Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
One year after the executive order creating the Golden Dome missile-defense initiative, the program has spent little of the $25 billion appropriated and remains stalled while officials and industry stakeholders debate classified elements of its space-based architecture. Small prototype contracts have been awarded, but major procurement and broad fu…
President Donald Trump will visit Iowa as mounting pressure in the farm economy and postponed biofuel decisions create strains for farmers and renewable-fuel producers. The stop is aimed at shoring up support in a state that is the nation's largest producer of corn, hogs and ethanol, even as farmers report cash-flow stress, lower crop prices and un…
Starbucks has made inventory reliability a central priority for CEO Brian Niccol, yet persistent shortages of everyday items across thousands of U.S. coffeehouses reflect deeper operational and technological failings. Interviews with current and former corporate employees, review of internal media and photographs, and company statements show recurr…
Citi has opened coverage on six leading European pharmaceutical groups with a constructive sector view. The bank rates AstraZeneca, Novartis and Roche as Buy, while GSK, Sanofi and Novo Nordisk receive Neutral ratings. Citi points to an unusually deep late-stage pipeline and expects resilient earnings growth driven by new product launches that larg…
After roughly four years of subdued initial public offering activity, Canada’s primary equity market is showing signs of revival for 2026. Market participants say high interest rates and inflation, regulatory friction, and other headwinds kept many firms out of the public markets, but recent equity market strength and a sizable October deal have en…
Allstate is trading like underwriting is still fully at the mercy of the cycle. But the profitability profile implied by a 30% ROE and a single-digit P/E suggests a structurally improved earnings engine. With the stock sitting below key moving averages and momentum still bearish, this is a mid-term long idea that looks like it’s offering entry rath…
Shares of major US health insurers fell sharply in premarket trading after the Centers for Medicare and Medicaid Services proposed a 0.09% increase to Medicare Advantage payment rates for 2027. The modest update, which CMS said produces just over $700 million in additional payments, came well below analyst expectations and has raised concerns about…
Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …
Futures tied to the S&P 500 and Nasdaq moved up on Jan. 27 as market participants prepared for a heavy roster of corporate earnings reports. Dow futures lagged after a sharp selloff in UnitedHealth linked to a government proposal to adjust Medicare insurer payment rates. The Federal Reserve begins a two-day policy meeting the same day, and a st…
Kepler Cheuvreux moved Atrium Ljungberg from Buy to Hold and left its price target unchanged at SEK 36, citing reduced upside after a 6% share rise since the October upgrade and a subdued funds from operations growth outlook. The research house forecasts negative FFO CAGR for 2025-2027, expects a sequential dip in rental income in Q4, and anticipat…
UnitedHealth said it expects adjusted 2026 earnings per share just above analysts' consensus, signaling initial benefits from recent medical cost-control measures. The company nevertheless flagged ongoing challenges in Medicaid and government-backed plans and noted that a proposed minimal Medicare Advantage rate increase weighed on insurer stocks.
Jefferies raised its price target for Caterpillar to $750 from $700 while retaining a Buy rating, pointing to a favorable 2026 outlook for the Construction Industries segment and possible upside in Resource Industries. The new target implies a 25x multiple on Jefferies' 2026 EBITDA estimate. The upgrade comes ahead of Caterpillar's January 29 earni…
Morgan Stanley trimmed its rating on Clearwater Analytics Holdings (CWAN) from Overweight to Equalweight and reduced its price target to $24.55 from $27.00 following the close of the company's go-shop period. The revised target reflects the agreed acquisition price of $24.55 per share, and follows a go-shop during which Clearwater solicited interes…
TD Cowen has initiated coverage of Zimmer Biomet (NYSE: ZBH) with a Buy rating and a $109 price target, implying about 25% upside from the current share price of $87.32. The firm points to a stronger growth and profitability outlook, underpinned by a 71.6% gross profit margin and 5.5% revenue growth over the past 12 months, while noting prior execu…
TD Cowen initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, noting solid early commercial traction for the iLet system but expressing concerns that projected revenue gains may not justify an outsized valuation. The firm highlighted strong recent top-line growth alongside signs of a potential slowdown in n…
TD Cowen began coverage of Stryker Corporation (NYSE: SYK) with a Hold rating and a $387 price target shortly before the company's upcoming earnings report. The firm praised Stryker's long run of organic growth and renewed focus on margins, while noting valuation metrics that present both potential upside and premium multiples. Recent corporate mov…
Dr Martens reported a decline in quarterly revenue and signalled broadly flat annual revenue growth after rolling back promotions, a move that depressed sales in Europe and the Asia-Pacific region. The company said U.S. customers were more accepting of full pricing, driving modest growth in the Americas, while management kept a forecast for signifi…
Spotify has pulled back sharply from its 52-week highs and is now sitting near short-term moving averages with an oversold RSI around 35. The tape still shows bearish momentum, but the dip is starting to look more like exhaustion than the start of a fresh breakdown. This trade idea is a defined-risk long that leans on mean reversion back toward the…
J.P. Morgan has put Legrand on a positive catalyst watch ahead of the group's fourth-quarter results due Feb. 12, reiterating an overweight rating and a €165 price target. The bank highlights upside versus consensus for the quarter, the company's exposure to robust data-center demand, a valuation discount relative to peers, and elevated short inter…
Fugro and Fraunhofer IWES have completed a geophysical site characterization in the German North Sea for the Federal Maritime and Hydrographic Agency (BSH). The April-May survey combined sub-bottom profiler and ultra-high-resolution multichannel seismic data to map seabed and sub-seabed structures, yielding a preliminary interpretation intended to …
Jefferies has reaffirmed a Hold rating and a $28.00 price target on Pinterest Inc (NYSE: PINS) ahead of the company’s earnings report on February 12. While acknowledging seasonally reasonable revenue plans and a resilient holiday ad market, the firm warned that Pinterest’s fiscal 2026 EBITDA margin assumptions may be vulnerable to downward revision…
Morgan Stanley has maintained an Overweight rating and a $7.00 price target on NIO, reflecting a potential 52% upside from the carmaker's prevailing share price of $4.61. The call follows the company's founder projecting a 40-50% compound annual growth rate in deliveries over the next two years, and centers on new premium models designed to improve…
BofA Securities lowered its 12-month price target on Brown & Brown (NYSE: BRO) to $90 from $94 while keeping a Neutral rating, citing the insurance broker's mixed fourth-quarter results. The company posted adjusted EPS of $0.93, ahead of the $0.91 consensus, but total revenue of $1.6 billion missed the $1.65 billion estimate and organic revenue dec…
Jefferies reiterated a Buy rating and a $750.00 price target on Spotify (SPOT) ahead of the company’s upcoming earnings release, pointing to potentially conservative fourth-quarter gross margin estimates and managed Q1 margin expectations. The firm foresees revenue acceleration in coming quarters driven by U.S. subscription price increases, while n…
BofA Securities has reaffirmed a Buy rating and a $1,672 price target on ASML, keeping the company as a Top Pick and valuing it at 31.0x CY27E EV/EBITDA. The broker's reassessment, informed in part by a discussion with Erik Hosler of xLight Inc., downplays near-term competitive threats from China’s domestic EUV efforts. Other analysts, including Be…
